PCMA represents several American managed care entities and has been an active participant in the national debate over the issue of high priced biotech Rx drugs.
As the controversy over Sovaldi’s $84,000 per therapy cost continues to build, the Pharmaceutical Care Management Association has released a study on the impact of the new Hepatitis C drugs on the overall costs to the US Medicare Part D pharmaceutical program (http://www.pcmanet.org/images/stories/uploads/2014/partdpremiumstudymilliman.pdf)
PCMA represents several American managed care entities and has been an active participant in the national debate over the issue of high priced biotech Rx drugs. Several of the PCMA’s members, including CVS Caremark, have publicly objected to the pricing of Sovaldi by the drug’s manufacturer, Gilead (http://goo.gl/vgFtvR ). Gilead, interestingly, is listed as a PCMA affiliate on the PCMA website (http://goo.gl/TwdtzY ).
It should be noted that the study was created for the PCMA by the respected actuarial service, Milliman.
Highlights:
The actuarial firm noted that their analysis was based on a representative 2015 Prescription Drug Plan (PDP) bid that was developed by using a comprehensive Medicare Care Part D database that utilized a defined standard benefit design.
Milliman emphasized that while the actual bids of the PDPs will vary based on populations and several other demographic variables, the firm used an estimate that models that entire Medicare population which enabled Milliman to generate Part D 2015 estimates with - and without - the new HCV product coverage.
A few other points that Milliman offers to readers of this report:
Milliman underscores that the report is limited only to the cost of the new HCV drugs and stresses that these cost impacts do not address the potential savings that these new PCV drugs may drive. The potential, overall savings that may result from the Sovaldi therapy is a major issue that Gilead, manufacturer of Sovaldi, has emphasized repeatedly in the public media (http://goo.gl/XH5w37 ).
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.